YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
94 hedge funds and large institutions have $140M invested in Y-mAbs Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 98 → 94 (-4)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Holders
94
Holding in Top 10
1
Calls
$17K
Puts
$16K
Top Buyers
| 1 | +$6.99M | |
| 2 | +$4.63M | |
| 3 | +$3.03M | |
| 4 |
Morgan Stanley
New York
|
+$2.61M |
| 5 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
+$562K |
Top Sellers
| 1 | -$2.22M | |
| 2 | -$1.89M | |
| 3 | -$1.89M | |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.34M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$1.17M |